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ABSTRACT: Radical surgery still represents the treatment choice for
several malignancies. However, local and distant tumor relapses remain the
major causes of treatment failure, indicating that a postsurgery consolidation
treatment is necessary. Immunotherapy with checkpoint inhibitors has
elicited impressive clinical responses in several types of human malignancies
and may represent the ideal consolidation treatment after surgery. Here, we
genetically engineered platelets from megakaryocyte (MK) progenitor cells
to express the programmed cell death protein 1 (PD-1). The PD-1 platelet
and its derived microparticle could accumulate within the tumor surgical
wound and revert exhausted CD8+ T cells, leading to the eradication of
residual tumor cells. Furthermore, when a low dose of cyclophosphamide
(CP) was loaded into PD-1-expressing platelets to deplete regulatory T cells
(Tregs), an increased frequency of reinvigorated CD8+ lymphocyte cells was observed within the postsurgery tumor
microenvironment, directly preventing tumor relapse.
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Surgery is the main therapeutic option for most solidtumors. However, the local and distal tumor relapses
frequently occur because of the incomplete resection of
tumors.1,2 Hence, there have been tremendous interests in
developing effective strategies to prevent cancer relapse after
surgery.3,4 For example, tumor antigen-specific CD8+ T cells
contribute to the eradication of residual tumor cells,5 especially
those that harbor neoantigens (mutant protein-derived
antigens).6−9 However, PD-L1 expression in tumors sup-
presses T cell responses by causing T cell exhaustion.10
Exhausted T cells are restrained by PD-L1 ligands through the
inhibitory receptors PD-1 disabling the production of immune
cytokines such as interferon-γ (IFN-γ), tumor necrosis factor-α
(TNF-α), granzyme B, and perforin.11,12
Blocking the PD-1/PD-L1 axis by using checkpoint
antibodies can reinvigorate exhausted T cells having led to
the eradication of the tumor in ∼30% of the patients with
melanoma and other types of cancers.13−15 However, more
than half of patients are not responsive or only transiently
responsive to PD-1/PD-L1 blockade due to the existence of
multiple immune evasion mechanisms.16 For instance, studies
indicate that there are many intrinsic and extrinsic tumor-
associated mechanisms of resistance to immunotherapy that
include loss of targeted tumor-associated antigens, down-
regulation of major histocompatibility complex (MHC)
molecules, expression of other immune checkpoint receptors,
and abundance of immune suppressive cell populations (Tregs,
type II macrophages, myeloid-derived suppressor cells
(MDSCs)).16 In particular, in addition to inhibiting effector
T cells, Tregs compete in the consumption of interleukin-2
(IL-2) in the tumor microenvironment further impairing the
proliferation of tumor infiltrated CD8+ T cells.17,18 Moreover,
activated Tregs may also directly kill T cells through perforin.19
Thus, abundant Tregs in tumor tissue are crucial obstacles to
achieve successful cancer immunotherapy.20 Depletion of
Tregs can significantly improve the response rate of PD-1/
PD-L1 blockade.14
As the monitor of vascular damage, platelets can accumulate
to the surgery wound.21,22 By employing this property, platelets
conjugated with anti-PD-L1 can accumulate within the tumor
surgery wound, reinvigorating exhausted CD8+ T cells, and
thus reduce postsurgical tumor recurrence and metastasis.23
Moreover, platelet membrane is used to design formulations
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for wound and inflammation targeting cancer treatment.24−27
However, since blood-originated platelets are non-nucleated
and terminally differentiated cells, they cannot be expanded ex
vivo and genetically manipulated to stably express transgenes,
which significantly limit their clinical use as payload for cancer
immunotherapy.28 In contrast, in vitro production of platelets
from megakaryocytes (MKs) can provide a large source of
platelets and be genetically modified.29,30 Herein, we
genetically engineered murine MKs to stably express murine
PD-1 and to produce mature platelets presenting PD-1 in vitro.
We then applied these cells to target tumor cells within the
surgical wound via reinvigoration of exhausted CD8+ T cells
(Figure 1). In addition to PD-L1 blockade, PD-1-expressing
platelets can also carry and transport cyclophosphamide, which
allows the depletion of Tregs within the tumor microenviron-
ment and further enhances the antitumor effects of CD8+ T
lymphocyte cells within the surgical tumor microenvironment.
Platelets are released from the bone marrow and lung
resident MKs.31 To produce platelets in large-scale, we treated
the murine MK progenitor cells L8057 with phorbol 12-
myristate 13-acetate (PMA). After stimulation, cell volume was
significantly increased, accompanied by proplatelet extension
(Figure S1A,B) and platelets release (Figure S1C,D). MKs
with larger cell volume containing polyploid nuclei were
observed, indicating MK maturation and readiness for releasing
the platelets (Figure S2). To generate PD-1-expressing
platelets, L8057 cell line stably expressing murine EGFP-PD-
1 was established by infection with lentivirus and selection with
puromycin (Figure S3).32 Remarkably, PD-1 was expressed
and localized on the cell membrane, as indicated by the
colocalization of fluorescence from EGFP and the cell
membrane dye Alexa Fluor 594-conjugated wheat germ
agglutinin (WGA594) (Figure 2A). PD-1 expression on
EGFP-PD-1 L8057 cells was confirmed by Western blot
(Figure 2B). CD41a, the marker of MKs, was intensively
expressed on PD-1 L8057 cell line (Figure S4A). After the
stimulation with PMA, PD-1-expressing L8057 cells underwent
maturation, and morphologically displayed typical peripheral
nuclei and increased cytoplasmic volume (Figure S4B).
CD42a, a marker of MK maturation, was expressed on the
cell membrane (Figure 2C). Moreover, the platelet surface
receptors glycoprotein VI (GPVI) and P-selectin were
expressed in mature PD-1 L8057 cells (Figure S4C,D).
Wright−Giemsa staining revealed that mature PD-1 L8057
cells contained polyploid nuclei (Figure 2D).
Mature MKs typically reside in bone marrow and lung
budding podosomes and prolong to form proplatelets.33
Proplatelets cross through the sinusoidal endothelium and
release platelets into the bloodstream.31,33 Similarly, mature
PD-1-expressing L8057 cells had budding podosomes, which
prolonged to form the proplatelets (Figure 2E). Notably, the
proplatelets were budded and extended from the cell
membranes to form pearl-like structures (Figure 2F). The
proplatelets finally disbanded and released platelets (Figure
S5A,B). MK cytoplasm containing EGFP-PD-1+ membrane
vesicles existed as a membrane reservoir for proplatelet
formation (Figure 2F). These PD-1-expressing membrane
vesicles fused to form tubular structure and budded from the
cell surface (Figure 2F). Purified platelets from the culture
media showed green fluorescence indicating that PD-1 was
present in the platelets (Figure 2G). Binding receptors
including GPVI and P-selectin were also expressed in platelets
released from L8057 cells (Figure S5C). Moreover, dynamic
light scattering (DLS) analysis showed that the average
diameter of the platelets was around 1.5 μm and with a ζ-
potential of −10 ± 2.6 mV (Figure 2H and Figure S5D). As
documented by cryo-scanning electron microscopy (CSEM)
and transmission electron microscopy (TEM), purified
platelets showed spherical morphology (Figure 2I,J). We
further quantitatively measured the platelet production from
PD-1-expressing L8057 cells and found optimal platelet
production at day 6 after stimulation with PMA (Figure 2K).
Platelets execute hemostasis, recruit other leukocytes for
host defense responses, and release several immunoreactive
molecules after adhering to vascular lesions.34 Collagen is the
primary subendothelial component for active platelet binding.
Figure 1. Schematic of the production of PD-1-expressing platelets and reinvigoration of CD8+ T cells. (A) Schematic shows L8057 cell line stably
expressing murine PD-1 and production of platelets. (B) PD-1-expressing platelets target tumor cells within the surgery wound. (C) PD-L1
blockade by PD-1-expressing platelets reverts exhausted CD8+ T cells to attack tumor cells.
As illustrated in Figure 3A,B, WGA Alexa-Fluor 594 dye-
labeled free and PD-1-expressing platelets showed similar
collagen adhesion ability. In contrast, blockade of the collagen
receptor GPVI reduced the collagen adhesion ability of the
platelets (Figure S6A). Thrombus formation by platelet
aggregation is another critical event of the hemostatic
response.35 Free and PD-1-expressing platelets efficiently
aggregated in response to agonistic stimulation with thrombin
(Figure S6B). Platelet microparticles (PMPs) are generated
from activated platelets.36,37 To examine whether PMPs are
generated from activated PD-1-expressing platelets upon
stimulation, we treated the platelets with thrombin in vitro.
Confocal laser scanning microscopy (CLSM), SEM, and TEM
images indicated the generation of PMPs from activated
platelets (Figure 3C and Figure S6C). Platelets became more
dendritic and expansive after the treatment with thrombin
(Figure 3C). Furthermore, DLS analysis detected the
generation of small particles, substantiating the release of
PMPs from activated platelets (Figure 3D).
Elevation of PD-L1 expression in tumor cells causes
exhaustion of T cells expressing PD-1.10 To investigate
whether PD-1 expressed platelets could bind to the surface
of the melanoma cells and block PD-L1, we incubated the PD-
1-expressing platelets with the B16F10 melanoma cells in vitro.
We observed that PD-1-expressing platelets bound to B16F10
cells and were then internalized by the cancer cells (Figure 3E
and Figure S7). In contrast, free platelets showed limited
ability to bind to the B16F10 cells (Figure 3E). To examine
whether the PD-L1/PD-1 interaction mediated the internal-
ization of platelets, we added anti-PD-L1 antibody to block
PD-L1 on the B16F10 cells. The confocal images showed that
PD-1 platelets binding was significantly reduced when PD-L1
antibody was preincubated with the cells (Figure S7A).
Furthermore, the EGFP-PD-1-expressing platelets colocalized
Figure 2. Production and characterization of platelets from PD-1-expressing L8057 stable cell line. (A) Confocal images present L8057 cell line
stably expressing murine EGFP-PD-1 on cell membranes. WGA Alexa-Fluor 594 dye was used to stain cell membrane (scale bar: 10 μm). (B)
Western blot analysis for evaluating the expression of PD-1 in L8057 cell line. L8 is short for L8057 cells. (C) EGFP-PD-1-expressing L8057 cells
stimulated with 500 nM PMA for 3 days, and immunostained to detect CD42a expression. (D) L8057 cells stimulated with 500 nM PMA for 3
days, and stained with Wright−Giemsa dye (scale bar: 10 μm). (E) Evolution process of PD-1-expressing proplatelet extended from MKs (scale
bar: 10 μm). (F) Morphology of PD-1 proplatelets extended from L8057 cells after 6 days of stimulation with 500 nM PMA. PD-1 proplatelets
extended from L8057 cells (scale bar: 10 μm). (G) Representative confocal images of purified PD-1-expressing platelets (scale bar: 10 μm). (H)
Size distribution of PD-1-expressing platelets measured by DLS. (I) CSEM image shows the morphology of PD-1-expressing platelets (scale bar: 1
μm). (J) Representative TEM image shows morphology and size of PD-1-expressing platelet (scale bar: 1 μm). (K) Number of platelets released
from PD-1-expressing L8057 cells after stimulated with 500 nM PMA (n = 5). Error bar, ± SD.
with DsRed-PD-L1 expressed by B16F10 melanoma cells,
indicating the physical interaction between PD-1 and PD-L1
(Figure 3F). To investigate the in vivo biodistribution of free
and PD-1-expressing platelets, Cy5.5-labeled platelets were
inoculated in mice via tail-vein injection. Free platelets showed
longer blood retention than PD-1-expressing platelets (14% vs
8% at 24 h) (Figure 3G). When Cy5.5-labeled platelets were
inoculated intravenously after tumor resection in B16F10
tumor-bearing mice, both free and PD-1 platelets could accu-
mulate in the residual tumor bed (Figure 3H,I). Meanwhile the
platelets intensively accumulated in the liver and spleen
(Figure 3H,I). GPVI is the collagen receptor on the platelets
Figure 3. In vitro and in vivo function of PD-1-expressing platelets. (A, B) Retention of platelets on collagen-coated or uncoated tissue culture
slides. Green color: EGFP; Red color: WGA Alexa-Fluor 594 dye (scale bar: 50 μm). Error bar, ± SD. (C) Confocal, CSEM, and TEM images of
PD-1-expressing platelets stimulated with thrombin. Platelet microparticles (PMPs) were released from the platelet (scale bar: 1 μm). (D)
Measurement of the size distribution of PD-1-expressing platelets at 30 min after activation by thrombin. PMPs were produced from the platelets.
(E) EGFP-PD-1-expressing platelets bound on the cell membrane of B16F10 cells. PD-1-expresing platelets or free platelets labeled with Cy5.5
were incubated with B16F10 cells for 20 h. WGA Alexa-Fluor 594 dye was used to stain the B16F10 cell membrane. The white arrows indicate the
PD-1 platelets binding on the cell membrane of the cancer cells (scale bar: 10 μm). (F) B16F10 cells were transfected with DsRed-PD-L1 plasmid
for 20 h, and then incubated with EGFP-PD-1 platelets for 20 h; the colocalization of EGFP-PD-1 platelets and DsRed-PD-L1 was detected (scale
bar: 10 μm). (G) Cy5.5-labeled free platelets and PD-1-expressing platelets were injected through the tail-vein in mice. Fluorescence was measured
at different time points (n = 3). Fluorescence intensity at 2 min as 1. Error bar, ±SD. (H) In vivo fluorescence images of free platelets and PD-1-
expressing platelets in major organs and residual tumor bed. (I) Fluorescence intensity per gram of tissue in major organs and tumors (n = 3). Error
bar, ± SD.
and is responsible for the platelets targeting the wound. PD-1
platelets and free platelets showed similar binding ability on
the collagen (Figure 3A). Therefore, the accumulation ability
in the surgical tumors is similar between the free platelets and
PD-1 platelets (Figure 3H).
To investigate whether PD-1-expressing platelets prevent
cancer relapse after surgery, we utilized the B16F10 melanoma
incomplete-tumor-resection model to mimic the postsurgical
local relapse (Figure 4A). Tumor-bearing mice were injected
intravenously with phosphate-buffered saline (PBS), free
Figure 4. PD-1-expressing platelets for inhibition of tumor progression in incomplete-surgery tumor model. (A) Schematic illustration of PD-1-
expressing platelets used for therapy in an incomplete-surgery tumor model. (B) In vivo bioluminescence imaging of the B16F10 tumor growth in
mice treated with PBS (G1), free platelets (G2), and PD-1-expressing platelets (G3). (C) Average tumor volumes of treated mice (n = 8). Data are
shown as the mean ± SEM. (D) Survival curves of mice receiving different treatments (n = 8). (E) Immunofluorescence of tumor sections showing
infiltration of CD4+ and CD8+ T cells (scale bar: 100 μm). (F)Representative plots and (G) quantification of T cells in tumors analyzed by flow
cytometry (gated on CD3+ T cells) (n = 3). Error bar, ± SD. (H) Representative plots and (I) quantification of GzmB in CD8+ T cells in tumors
analyzed by the flow cytometry (gated on CD8+ T cells) (n = 3). Error bar, ± SD. Throughout, NS, not significant; *P < 0.05; **P < 0.01; ***P <
0.001. (C, G, I) One-way ANOVA with Tukey posthoc test analyses were carried out to do the analyses, or (D) by log-rank (Mantel-Cox) test.
platelets (2 × 108), or PD-1-expressing platelets (2 × 108).
After platelet infusion, tumors were resected to remove ∼90%
of the tumor mass. After surgery, mice received additional
treatment during the period of wound healing (Figure 4A). We
observed tumor growth delay in mice treated with PD-1-
expressing platelets as assessed by monitoring the tumor
bioluminescence and measuring the tumor size (Figure 4B,C,
and Figure S8A). In contrast, tumors rapidly progressed in
mice that received free platelets or PBS (Figure 4B,C, and
Figure S8A). There were 25% of mice receiving PD-1-
expressing platelets that survived more than 60 days without
obvious weight loss or other signs of toxicities (Figure 4D and
Figure S8B). The major organs such as liver, spleen, kidney,
heart, and lung were collected and assessed by immunohis-
tochemistry to assess the systemic toxicity. There was no
obvious sign of organ damage observed in the platelets treated
Figure 5. In vivo antitumor effect of cyclophosphamide-loaded PD-1-expressing platelets in incomplete-surgery tumor model. (A) Average tumor
volumes of mice (n = 8) treated with PBS (G1), cyclophosphamide (CP) (G2), PD-1-expressing platelets (G3), CP-free platelets (G4), and CP-
loaded PD-1-expressing platelets (G5). Data are shown as the mean ± SEM. ***, Compared with PBS control. (B) Survival curves of the treated
mice. (C) Quantification of FoxP3 expression in CD4+ T cells within the tumors analyzed by the flow cytometry (gated on CD4+ T cells) (n = 3).
(D) Representative plots and (E) quantification of Ki67 in CD8+ T cells within the tumors analyzed by the flow cytometry (gated on CD8+ T cells)
(n = 3). (F) Representative plots and (G) quantification of CD8+ and CD4+ T cells within tumors analyzed by the flow cytometry (gated on CD3+
T cells) (n = 3). (H) Representative plots and (I) quantification of GzmB in CD8+ T cells within the tumors analyzed by the flow cytometry (gated
on CD8+ T cells) (n = 3). (J, K) Immunofluorescence of the tumors showing CD8+ T cell infiltration (scale bar: 100 μm). Error bar of C, E, G, I,
K, ± SD. Throughout, NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001. (A, C, E, G, I, K) Two-way ANOVA with Tukey posthoc test
analyses were carried out to do the analyses or (B) by log-rank (Mantel-Cox) test (B).
mice (Figure S9). Remarkably, we observed increased
frequency of CD8+ TILs in the tumor of mice treated with
PD-1-expressing platelets (Figure 4E−G), and T cells
exhibited increased expression of cytotoxic protein granzyme
B (GzmB), indicating that PD-1-expressing platelets can revert
T cell exhaustion within the tumor microenvironment (Figure
4H,I).
Low doses of cyclophosphamides can improve immune
responses in various murine tumor models and patients, which
is generally attributed to selective depletion of Tregs.38−40 To
counter Tregs at the tumor site, we loaded the cyclo-
phosphamide into the platelets. We found that platelets
could internalize and release cyclophosphamide within 24 h in
vitro (Figure S10). To investigate the simultaneous antitumor
effect of PD-L1 blockade and cyclophosphamide-induced
depletion of Tregs, we used the same B16F10 melanoma
model with incomplete-tumor-resection. In this model, while
cyclophosphamide and PD-1-expressing platelets showed
limited results when used as single agents (Figure 5A and
Figure S11A), tumor progression was significantly suppressed
in mice treated with cyclophosphamide-loaded PD-1-express-
ing platelets (P < 0.001) (Figure 5A and Figure S11A). Treg
depletion by cyclophosphamide and PD-L1 simultaneously
blockade by PD-1 improved the survival of the treated mice
(Figure 5B).
We further investigated the frequencies of the CD4+ Tregs
and CD8+ TILs in the tumor upon treatment. Free
cyclophosphamide and cyclophosphamide-loaded platelets
selectively depleted Tregs within the tumor (Figure 5C and
Figure S11B) and increased the frequency of Ki67+ T cells
(Figure 5D,E). Of note, despite PD-1-expressing platelets
having limited effect in reducing Tregs, they still increased the
frequency of Ki67+ T cells (Figure 5D,E). Remarkably, the
frequency of CD8+ TILs was significantly increased in tumors
collected from mice treated with cyclophosphamide-loaded
PD-1-expressing platelets (Figure 5F,G), and these cells
showed GzmB expression (Figure 5H,I). Immunofluorescence
staining also revealed enhanced density of infiltrated CD8+ T
cells in the mice treated with cyclophosphamide-loaded PD-1-
expressing platelets as compared to control mice (Figure 5J,K).
Mice treated with a low dose of cyclophosphamide, and
cyclophosphamide-loaded platelets showed delayed hair
growth in the abdomen and slighted weight loss (Figure
S11A,C). These results demonstrated that the combined
utilization of PD-1-expressing platelets and cyclophosphamide
effectively disrupted the immune blockade of PD-L1 and
depleted the Tregs, leading to the reduced tumor relapse rate
after surgery.
In summary, we generated a cellular drug delivery system
that leverages PD-1-presenting platelets for enhanced cancer
immunotherapy after surgery. The PD-1-expressing platelets
could accumulate in the surgical wound sites upon intravenous
infusion, block PD-L1 on residual tumor cells, and revert
exhausted CD8+ T cells to eradicate residual tumor cells. Such
platelets could also function as a carrier of drugs, such as
cyclophosphamide, to simultaneously disrupt the immune
suppressive effects of PD-L1 and deplete Tregs, and promote
the emergence of CD8+Ki67+GzmB+ lymphocytes in the
surgical tumor microenvironment. This cell-mediated delivery
strategy can be further exploited to deliver other checkpoint
blockade inhibitors toward the tumor site as well as other
immunomodulatory drugs.41,42
Chemicals and Reagents. Cyclophosphamide, thrombin,
Wright−Giemsa solution, and phosphatase inhibitor cocktail
were from Sigma-Aldrich. Murine PD-1 and PD-L1 antibodies
were from Thermo Scientific and Sigma-Aldrich, respectively.
Murine CD41a (ab63983), CD42a (ab173503), CD4, and
CD8 antibodies were from Abcam. P-Selectin (sc-8419) was
from Santa Cruz biotechnology. Murine GPVI (MAB6758)
antibody was from R&D Systems. CD3, CD4, CD8, Ki67, and
Foxp3 antibodies for FACS analysis were from Biolegend Inc.
Wheat germ agglutinin (WGA) Alexa Fluor 488 and 594 dyes
were from Thermo Scientific.
Cell Culture. HEK293T were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS). Mouse megakaryocyte cell line
L8057 was kindly provided by professor Alan Cantor (Boston
Children’s Hospital, Dana-Farber Cancer Institute) and was
cultured in RPMI 1640 with 20% FBS. The murine melanoma
cell line B16F10 was obtained from the American Type
Culture Collection. For bioluminescent in vivo tumor imaging,
B16F10-luc cells were kindly provided by Dr. Leaf Huang at
UNC. B16F10 cells were cultured in DMEM supplemented
with 10% FBS.
Plasmid and Stable Cell Line. Lentivirus vector encoding
murine PD-1 fused at C-terminal region with GFP-tag (pLenti-
C-mGFP-PD-1-puro) and Lenti-vpak packaging kit and
transfection reagent were obtained from Origene. Mouse
DsRed-PD-L1 plasmid was obtained from Sino biologi-
cal. L8057 cells were infected with the lentivirus and incubated
with 6 μg/mL polybrene. After infection, L8057 cells were
cultured in RPMI 1640 with 20% FBS and with 1 μg/mL
puromycin to select cell lines stably expressing murine PD-1.
Established EGFP-PD-1 L8057 cells were maintained in 20%
FBS complementary with 0.5−1 μg/mL puromycin.
Preparation of Platelets from L8057 Cells. L8057 cells
and PD-1-expressing L8057 cells were cultured in RPMI 1640
with 20% FBS. For maturation and differentiation, L8057 cells
were stimulated with 100−500 nM PMA for 3 days. Cells were
then cultured for another 6 days to produce proplatelets and
platelets. To isolate platelets, the culture medium was
centrifuged at 1500 rpm for 20 min to remove the cells.
Supernatant was then centrifuged at 12 000 rpm for 20 min at
room temperature. Platelet precipitate was resuspended in
Tyrode’s buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM
KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM HEPES, pH
7.4) or PBS with 1 μM PGE1. To active platelets, 0.5 U
thrombin/mL was added to the platelet suspension. PGE1 was
removed prior to platelet activation.
Wright−Giemsa Stain. L8057 cells stimulated with 100−
500 nM PMA for 3 days were harvested and washed with PBS
buffer. Cells were then fixed in absolute methanol for 5 min,
stained in Wright−Giemsa stain solution for 5 min, washed
with PBS buffer, and observed under microscope with 40×
objective.
Cell Immunofluorescent Assay. EGFP-PD-1-expressing
L8057 cells were washed with PBS and fixed with 4%
paraformaldehyde for 10 min. Then the cells were washed with
PBS, incubated with 0.2% Triton X-100 for 5 min, and blocked
with the buffer containing 3% BSA for 1 h. After that, cells
were stained with CD41a, CD42a, and P-selectin antibodies
overnight at 4 °C. After washing with PBS, cells were stained
with Rhodamine-conjugated secondary antibody (KPL)
diluted at room temperature and kept in the dark for 1 h.
The nucleus was stained with DAPI for 10 min. After washing
with PBS, confocal microscopy was performed on a FLUO-
VIEW laser scanning confocal microscope (Zeiss) in sequential
scanning mode using a 63× objective.
Western Blot. Immunoblotting analysis was performed as
previously described.43 L8057 control cells and L8057 cells
stably expressing EGFP-PD1 were lysed with RIPA lysis buffer
(Thermo Scientific), and cell lysates resolved on 12% SDS-
PAGE. Immunoblotting was incubated with PD-1, CD41a,
CD42a, P-selectin, GPVI, and β-actin antibodies, followed by
enhanced chemiluminescence (ECL) detection (Thermo
Scientific).
B16F10 Cell Binding Assay. B16F10 cells were seeded in
confocal wells. EGFP-PD-1-expressing platelets and free
platelets (∼0.5 × 108 cell/well) labeled with cy5.5 were
added to the culture medium and incubated with the B16F10
cells overnight. Wheat germ agglutinin (WGA) and Alexa
Fluor 594 conjugate were added to stain the cell membrane of
B16F10 for 10 min. The nucleus was stained with DAPI for 10
min. After washing with PBS, confocal microscopy was
performed on a confocal microscope (Zeiss) in sequential
scanning mode using a 63× objective.
Collagen Binding Assay. Briefly, 200 μL of the collagen
solution (Murine collagen type I/III (Bio-Rad) reconstituted
in 0.25% acetic acid at concentration of 2.0 mg/mL) was
added to a 96-well plate and incubated overnight at 4 °C. Prior
to the collagen binding study, the plate was blocked with 2%
BSA and washed with PBS. Platelets were stained with WGA
Alexa Fluor 594 for 30 min, washed with PBS, and added to
collagen-coated or non-collagen-coated plates (∼1 × 107 cells/
well) in triplicate. After 30 s of incubation, plates were washed.
Retained platelets were dissolved with 100 μL of DMSO for
fluorescence quantification using a TeCan Infinite M200
reader. For confocal imaging, the collagen solution was added
to the confocal well and incubated overnight at 4 °C (∼1 × 108
cells/well). Wells were blocked with 2% BSA, and WGA Alexa
Fluor 594-labeled platelets were incubated with collagen for 2
min, washed with PBS, and analyzed by confocal microscopy
using a confocal microscope (Zeiss) in sequential scanning
mode using a 63× objective.
Aggregation Assay. Aggregation of platelets was assessed
using confocal imaging. Platelets were labeled with WGA Alexa
Fluor 594, loaded to the confocal well, and incubated with 0.5
U/mL of thrombin for 30 min. Confocal microscopy was
performed on a confocal microscope (Zeiss) in sequential
scanning mode using a 63× objective.
Drug Loading and Release. To prepare cyclophospha-
mide-loaded platelets, 100 μg of purified platelets and 100 μg
of cyclophosphamide were gently mixed in 1 mL of PBS and
incubated for 2 h at 37 °C.44,45 Platelets were then washed
with PBS by centrifugation at 12 000 rpm. For electroporation
shock method, 100 μg of purified platelets and 100 μg of
cyclophosphamide were gently mixed in 1 mL of electro-
poration buffer (1.15 mM potassium phosphate pH 7.2, 25
mM potassium chloride, 21% Optiprep) at room temperature.
Samples were electroporated at 300 V and 150 μF in 0.4 cm
electroporation cuvettes using a MicroPulser Electro-porator
(Bio-Rad). Electroporation cuvettes containing samples were
then incubated for 30 min for the membrane recovery.
Platelets were washed with PBS by centrifugation at 12 000
rpm.46−48 The release of cyclophosphamide from platelets
(100 μg/mL) was analyzed in PBS (pH 7.2) at different time
points at 37 °C. The amount of cyclophosphamide released
was quantified by using a UV−vis spectrophotometer at 205
nm.49,50
Circulation. PD-1-expressing platelets and free platelets
produced from L8057 cells were labeled by NHS-Cy5.5.
Labeled platelets (∼2 × 108 cells) were washed with PBS and
injected intravenously via tail-vein in C57BL/6 mice in 200 μL
of final volume. Peripheral blood was collected at different time
points after platelet injection, and fluorescence of the serum
was measured.
Biodistribution. Free platelets and PD-1-expressing
platelets produced from L8057 cells were labeled by NHS-
Cy5.5 in PBS. Following incubation overnight, Cy5.5-labeled
platelets (∼2 × 108 cells/mouse) were washed with PBS and
infused in melanoma tumor-bearing C57BL/6 mice. The
control group was injected with PBS. After 24 h, mice were
euthanized, and tumors and organs were harvested. Fluo-
rescence imaging and average radio intensities were recorded
using a Xenogen IVIS spectrum imaging system.
In Vivo Antitumor Effects. B16F10 luciferase-tagged
B16F10 (1 × 106 cells/mouse) melanoma tumor cells were
transplanted into the right flank of C57BL/6J mice. When the
tumor volumes were around ∼130 mm3, the tumors were then
resected, leaving about 15 mm3 (∼10%) tumor to mimic the
residual tumors in the surgical bed. Briefly, animals were
anesthetized in an induction chamber using isoflurane (up to
5% for induction; 1−3% for maintenance), and anesthesia was
maintained via a nose cone. The tumor area was clipped and
aseptically prepped. Approximately 90% of the tumor was
removed using sterile instruments. The wound was closed
using an Autoclip wound closing system. The mice were
randomly divided into groups (n = 8). Mice were intravenously
injected with PBS, free platelets (∼2 × 108 cells/mouse), PD-1
platelets (∼2 × 108 cells/mouse), cyclophosphamide (20 mg/
kg), cyclophosphamide-loaded free platelets (∼2× 108 cells/
mouse), or cyclophosphamide-loaded PD-1-expressing plate-
lets (∼2 × 108 cells/mouse). Immediately after treatment,
tumor resection was carried out within 10 min, one mouse by
one mouse. The tumor burden was monitored via tumor
bioluminescence. Images of the mice bearing tumor were taken
using an IVIS Lumina imaging system (PerkinElmer). Tumor
size was measured with a digital caliper. The tumor volume
(mm3) was calculated as (long diameter × short diameter2)/2.
Once the mice exhibit signs of impaired health or when the
volume of the tumor exceeded 1.5 cm3, the mice were
euthanized with CO2.
Tissue Immunofluorescent Assay. Tumors were har-
vested from the mice and snap frozen in optimal cutting
medium (O.C.T.). Ten micrometer sections were cut using a
cryotome and mounted on slides. Frozen tumor sections were
incubated in PBS for 15 min to remove the embedding
medium. Specimens were blocked with the buffer containing
3% BSA, incubated with CD4 and CD8 antibodies (1:50 in 3%
BSA) overnight, washed with PBS, stained with TRITC
secondary antibody (KPL) diluted in 1.5% BSA at room
temperature, and kept in the dark for 1 h. The nucleus was
stained with DAPI and washed with PBS. Confocal microscopy
was performed on a FLUO-VIEW laser scanning confocal
microscope (Zeiss) in sequential scanning mode using a 40×
objective.
Statistical Analysis. All results are expressed as the mean
± SD or the mean ± SEM as indicated. Biological replicates
were used in all experiments unless otherwise stated. One-way
or two-way analysis of variance (ANOVA) and Tukey posthoc
tests were used when more than two groups were compared
(multiple comparisons). Survival benefit was determined using
a log-rank test. All statistical analyses were performed using the
IBM SPSS statistics 19. The threshold for statistical
significance was P < 0.05.
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